Sage Journals: Discover world-class research

Open access

Research article

First published 2021-08-31

Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing,Combining EGFR Inhibitors with Naproxen,and Effects on RNA Expression

Ronald A. Lubet, Amit Kumar, Jennifer T. Fox [...]

Bladder Cancer

Retricted access

Case report

First published 2022-1

When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment

Mengwei Li, Jun Xiang, Chaoran Zhang

European Journal of Ophthalmology

Retricted access

Other

First published 2012-8

EGFR Inhibitor Therapy for Laryngeal Papillomatosis

Matthew Moldan, Bruce Bostrom, Meixia Liu [...]

Otolaryngology–Head and Neck Surgery

Open access

Research article

First published 2010

Inhibition of MLK3 Decreases Proliferation and Increases Antiproliferative Activity of Epidermal Growth Factor Receptor (EGFR) Inhibitor in pancreatic cancer cell Lines

Sreenivasa R. Chandana, Cheryl M. Leece, Kathleen A. Gallo [...]

Cancer Growth and Metastasis

Free access

Announcement

First published 2007-10

MUC-1 (CA 15–3 Antigen) as a Highly Reliable Predictor of Response to EGFR Inhibitors in Patients with Bronchioloalveolar Carcinoma: An Experience on 26 Patients

A. Bearz, R. Talamini, E. Vaccher [...]

The International Journal of Biological Markers

Open access

Other

First published 2026-3

EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors

Rajdeep Chakraborty, Pallavi Khodlan, Arthur Chien [...]

Journal of Pharmacology and Pharmacotherapeutics

Retricted access

Research article

First published 2019-6

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series

Jennifer G. Le-Rademacher, Kendrith Rowland, Pamela J. Atherton [...]

American Journal of Hospice and Palliative Medicine®

Open access

Research article

First published 2025

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study

Qi-An Wang, I-Lin Tsai, Chien-Yu Lin [...]

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2012-6

EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC

Kimberly J Gorden, Parvin Mesbah, Jill M Kolesar

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2022

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer

Xiaotong Lu, Jingbo Wang, Chunyu Wang [...]

Clinical Medicine Insights: Oncology

Search results